A research group from the Uniformed Services University of the Health Sciences (USU), in collaboration with European researchers, demonstrated that the peptic ulcer bacterium Helicobacter pylori (H. pylori) can reach the blood circulation. Thus, the bacterium can disseminate in the body and may cause other chronic inflammatory conditions of unknown origin, such as atherosclerosis and rheumatoid arthritis.
Andre Dubois, MD, PhD, professor of medicine, surgery, and emerging infectious diseases, and chief, Laboratory of Gastrointestinal and Liver Studies at USU, and members of his research group, Drs. Cristina Semino-Mora and Hui Liu, co-authored the article with European researchers led by Dr. Thomas Borén, professor of biochemistry and biophysics at Umeå University, Umeå, Sweden.
Dubois latest observations elaborate on the 1980s landmark studies by the 2005 Nobel laureates Barry Marshall and Robin Warren. These Australian investigators demonstrated that H. pylori is the cause of gastritis, peptic ulcers and stomach cancer, one of the most common types of cancer worldwide. Dubois research group subsequently showed that H. pylori could also invade normal and cancerous gastric epithelial cells. The latest research of the USU team now demonstrates that, in addition, H. pylori can enter the stomachs blood vessels and attach to red blood cells.
The mechanism of this attachment relies on proteins (adhesins) that are located on the bacterial surface and bind to carbohydrates located both on the stomach cell surfaces and on red blood cells. This firm attachment allows survival and persistence of the microbe in the acidic and turbulent stomach environment, and its role in the blood circulation may be clarified by the present observations.
Importantly, H. pylori attachment to red blood cells is mediated by the SabA adhesin, which has a different composition among different H. pylori strains from different patients and the host carbohydrates to which SabA attaches also varies among individuals. As a result, the SabA adhesin may determine the inherent feature of adaptation to cell surface characteristics of the individual host. Because H. pylori can adjust its adherence properties both for the individual gastric mucosa of the particular host, it also can adapt to the defenses constructed by the host in response to infection during chronic inflammation. Thus, the outcome of the H. pylori infection will depend on how the bacterium can adapt to the host defenses and vice-versa.
The research paper was published in the October issue of the PLoS Pathogens Journal.
Source: Uniformed Services University of the Health Sciences (USU)Â Â Â Â
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.